Share this article
Share this article
ResearchAndMarkets.com s offering.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as living drugs.
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an an
Maryland Stem Cell Research Commission Announces over $6 Million in Awards to Accelerate Cures
COLUMBIA, Md. (May 10, 2021) The Maryland Stem Cell Research Commission has approved funding to its second round of 2021 recipients for a total of $6,052,901. The Commission has also appointed Amritha Jaishankar, Ph.D., the current MSCRF Director – Programs & Strategic Alliances, to succeed Dan Gincel, Ph.D., as Executive Director of the MSCRF, effective May 14, 2021.
Established under the Maryland Stem Cell Research Act of 2006, the Maryland Stem Cell Research Fund (MSCRF) promotes state-funded stem cell research and cures through grants to both public and private entities in Maryland. MSCRF is currently budgeted to commit up to $8.2 million, in aggregate, in FY2022 to fund grants under all of its RFAs.
Share this article
Share this article
ResearchAndMarkets.com s offering.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as living drugs.
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an a
Share this article
Share this article
ResearchAndMarkets.com s offering.
The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient s immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy.